OncoSil Registry Data Shows Pancreatic Cancer Survival Beyond Trial Benchmarks
OSPREY registry data presented at ESGE Days 2026 shows encouraging real-world survival outcomes for LAPC patients
Interim results from the OncoSil Medical OSPREY Registry were presented at ESGE Days 2026 on 15 May 2026, delivering real-world clinical data on the OncoSil™ device across multiple European centres. The presentation, delivered by Dr Enrique Vázquez-Sequeiros from University Hospital Ramón y Cajal, Madrid, covered a 64-patient interim analysis drawn from centres in Austria, Greece, Italy and Spain, with total registry enrolment now exceeding 80 patients.
The headline safety finding from the interim analysis was unambiguous: no Grade ≥3 adverse device effects (ADEs) and no serious adverse device effects (SADEs) were reported across the cohort.
When big ASX news breaks, our subscribers know first
What the interim findings show
Safety profile
ADEs were reported in 15.6% of patients, consisting primarily of mild Grade 1 abdominal pain and one Grade 2 fatigue event. The absence of more severe events was the standout finding:
- No Grade ≥3 ADEs reported
- No serious adverse device effects (SADEs) reported
The investigators concluded that OncoSil™ treatment alongside gemcitabine-based chemotherapy was safe and well tolerated in routine practice.
Disease control and surgical downstaging
The local Disease Control Rate at 12 weeks post-implant demonstrated meaningful tumour control across both treatment lines:
- 91.4% in patients receiving first-line chemotherapy
- 77.8% in patients receiving second-line chemotherapy
A subset of patients achieved surgical downstaging following OncoSil™ treatment. The resection outcomes were as follows:
- 7 patients underwent surgical resection with curative intent following OncoSil™ treatment
- 5 of 7 patients (71.4%) achieved R0 resection margins (complete microscopic removal of the tumour)
- 2 of 7 patients (28.6%) achieved R1 resection margins
Overall survival outcomes
Median overall survival figures, segmented by implant timing, showed a notable improvement over historical benchmarks. Prospective clinical trials evaluating first-line gemcitabine plus nab-paclitaxel alone in unresectable locally advanced pancreatic cancer (LAPC) have reported median overall survival ranging from 12.7 to 18.8 months. The OSPREY interim data compared favourably against this range.
| Patient Group | Local Disease Control Rate (12 weeks) | Median Overall Survival | Surgical Resection Outcome |
|---|---|---|---|
| First-line chemotherapy, implanted ≤4 months | 91.4% | 20.6 months | 3 of 7 resected patients from this cohort |
| First-line chemotherapy, implanted 4–12 months | 91.4% (combined first-line rate) | 22.0 months | 3 of 7 resected patients from this cohort |
| Second-line chemotherapy, implanted ≤4 months | 77.8% | N/A | 1 of 7 resected patients from this cohort |
The median overall survival of 20.6 months and 22.0 months observed in first-line patients enrolled in the OSPREY Registry represents a notable improvement over the historical benchmark range of 12.7 to 18.8 months.
Why real-world data matters for OncoSil investors
The OSPREY Registry is a post-market, multi-centre, observational and prospective registry. Its purpose is to evaluate the safety and effectiveness of OncoSil™ as it is used in routine clinical settings, rather than under the controlled conditions of a formal clinical trial.
This distinction matters. Controlled trials enrol carefully selected patient populations and operate under tightly managed protocols, which can produce results that do not always replicate in everyday practice. When a real-world registry generates outcomes that mirror or exceed those seen in trials, it provides a meaningful signal for physician adoption and supports the commercial and reimbursement case for the device.
The disease context underscores why this data is significant. Pancreatic cancer affects approximately 500,000 people globally each year. Unresectable LAPC carries a poor long-term prognosis, and treatment options remain limited. OncoSil Medical targets this indication through intratumoural delivery of Phosphorus-32 microparticles alongside chemotherapy, enabling a greater radiation dose to be delivered directly into the tumour while sparing surrounding tissue.
Real-world data that replicates trial-level outcomes supports commercial uptake in the 30+ countries where OncoSil™ is currently approved for sale.
Nigel Lange, CEO & Managing Director, OncoSil Medical
“These results demonstrate that the safety profile and efficacy outcomes associated with OncoSil™ can also be achieved in routine real-world clinical practice across multiple centres in Europe.”
The next major ASX story will hit our subscribers first
What comes next for OncoSil Medical
The OSPREY Registry remains ongoing, with total enrolment now exceeding 80 patients beyond the 64-patient interim analysis presented at ESGE Days 2026. Continued enrolment will expand the evidence base and provide a larger dataset for future analyses.
OncoSil™ holds CE Marking approval for both the EU and the UK, and carries breakthrough device designation in Europe and the United States. The device is currently approved for sale in 30+ countries, with commercial treatments already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.
Dr Enrique Vázquez-Sequeiros, University Hospital Ramón y Cajal, Madrid
“These findings further support the role of OncoSil™ as a valuable addition to the treatment pathway for this highly challenging disease.”
As the registry continues to enrol patients across its European network, the accumulation of real-world clinical data strengthens both the commercial and clinical case for OncoSil™ as the company builds its presence across approved markets.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 subscribers are already getting the edge on market-moving announcements. Click the “Free Alerts” button to make sure the next major healthcare update reaches you before the market moves.